Gilead Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Gilead Sciences sits in the top decile of US sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count).

504 total trials 26 currently recruiting 346 completed early-phase tilt top decile by trial count

Gilead Sciences: 504 sponsored US clinical trials, 26 recruiting.

Gilead Sciences sponsors 504 registered US clinical trials on ClinicalTrials.gov, 26 of them currently recruiting, and 346 completed. 164 of these trials are in Phase 3-4 (later-stage) and 317 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 20 trials.

Top-decile sponsor footprint

Gilead Sciences ranks in the top decile of sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 34/100

346 of 445 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

What is open in the Gilead Sciences pipeline

26 recruiting of 504 indexed (5% open); 346 completed (69%).

Phase mix: 164 late (III/IV) vs 317 early (I/II) (early-phase heavy).

Top condition: HIV-1-infection (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Gilead Sciences: open-pipeline peers nationwide

Peers matched on 504 registered trials and 5% open enrollment, not the therapeutic-area sidebar.

Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20% Total trials Recruiting share Gilead SciencesH. Lee Moffitt Cancer Center and Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)Boehringer IngelheimNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Creighton UniversityAlmirall, S.A.Cordis USDefense and Veterans Center for Integrative Pain Management
Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 504 trials (± recruiting share)

Sponsors near 5% open enrollment (± trial volume)

What to do with this Gilead Sciences page

504 registered trials is a research-attention snapshot, not an endorsement of Gilead Sciences or any single study.

  • 26 of Gilead Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV-1-infection is the condition Gilead Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Gilead Sciences pipeline card: 504 registered trials from official public datasets.Report a data error.